Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Hansa Biopharma logo — We are dedicated to bring innovative treatments to people li...

Hansa Biopharma

We are dedicated to bring innovative treatments to people living with rare immunological diseases.

Founded 2007 Sweden Sweden 144 employees Post Ipo Equity Total: $442.20M Biotechnology, Health Care

General Information

Company Name Hansa Biopharma
Founded Year 2007
Location Sweden Sweden +1
Employees 144
Industries Biotechnology, Health Care
Funding Stage Post Ipo Equity
Social

Get notified when Hansa Biopharma moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Hansa Biopharma

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company founded in 2007 with a headquarters in Sweden. The company is dedicated to bringing innovative treatments to people living with rare immunological diseases. Hansa Biopharma's mission is to develop and commercialize innovative and life-altering treatments for patients with rare immunological conditions. The company's team of scientists is focused on developing immunomodulatory treatments for organ transplants, rare IgG-mediated autoimmune conditions, gene therapy, and exploring the potential application of the technology platform in oncology. The company's recent milestone includes a $70.00M grant investment on 18 July 2022, with the investor being Novaquest Capital Management. Hansa Biopharma is positioned as a valuable player in the biotechnology and healthcare industries, with a clear focus on addressing unmet medical needs in the rare disease space. Their commitment to advancing innovative therapies and attracting significant investments indicates a promising trajectory for both the company and potential investors.

Taxonomy: Biopharmaceuticals, Clinical development, Drug discovery, In vitro diagnostics, Organ transplantation, Autoimmune diseases, Gene therapy, Oncology, Antibody cleaving enzyme technology, Immunomodulatory treatments, Rare diseases, Orphan drugs

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• 6
Investor Investor Investor
•••• •••• 		12 Apr 2024
Grant •••••• 1
Investor
18 Jul 2022

Hansa Biopharma Alternatives & Competitors

Hansa Biopharma vs
Dicerna Pharmaceuticals
Dicerna Pharmaceuticals

Pioneering breakthroughs in genetic disorders and liver diseases using RNA interference technology.

Post Ipo Equity
201-500 employees
Biotechnology, Health Care
Compare Hansa Biopharma vs Dicerna Pharmaceuticals
Hansa Biopharma vs
Kalobios Inc
Kalobios Inc

Advancing Treatment Solutions for Respiratory Diseases and Rare Cancers

Post Ipo Equity
4 employees
Biotechnology
Compare Hansa Biopharma vs Kalobios Inc
Hansa Biopharma vs
Wilson Therapeutics
Wilson Therapeutics

Innovative pathways to treat rare conditions and enhance patient lives

Post Ipo Equity
Biotechnology, Health Care
Compare Hansa Biopharma vs Wilson Therapeutics

FAQ About Hansa Biopharma

We are dedicated to bring innovative treatments to people living with rare immunological diseases.
Hansa Biopharma was founded in 2007.
Hansa Biopharma is headquartered in Sweden.
Hansa Biopharma operates in the following industries: Biotechnology, Health Care.
Hansa Biopharma has approximately 144 employees.
Hansa Biopharma has completed 2 funding rounds, raising a total of $442.20M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Hansa Biopharma include Dicerna Pharmaceuticals, Kalobios Inc, Wilson Therapeutics, Maddie Riewoldt's Vision, Onspira Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Hansa Biopharma and Dicerna Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Hansa Biopharma and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy